You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical System for Measurement of Oral Crest Height Change in Dental Radiographs

    SBC: Imagination Software Corporation            Topic: NIDCR

    DESCRIPTION (provided by applicant): Twenty-six percent of the population twenty years and over have destructive periodontal disease (gt 4 mm loss of bone height). Alveolar bone height correlates well with subsequent tooth loss. Moreover, it has been foundthat periodontal disease correlates with other diseases, e.g., atherosclerosis and diabetes. Proper diagnosis, treatment, maintenance, and patie ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Repair of Bone Defects with Human Autologous Pluripotent Very Small Embryonic lik

    SBC: Caladrius Biosciences            Topic: NIDCR

    DESCRIPTION (provided by applicant): Bone loss due to fractures and disease is a serious medical condition in the US affecting millions of Americans. It is particularly a problem with oral craniofacial disorders were the costs of treating damage exceeds60 billion annually. Furthermore, periodontitis is associated with systemic disorders such as diabetes mellitus, preterm low birth weight, and car ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of

    SBC: EPIVAX, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by optimizing the clinical delivery vehicle and treatment protocol, and by identifying correlates of efficacy in preparation for Phase 1 clinical trials. More than 13,000 children in the U.S. are diagnos ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Antifibrotic Therapy for Chronic Kidney Disease

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Chronic kidney disease (CKD) remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Few, if any, of the currently practiced therapeutic strategies oppose the molecular and cellular program of fibrosis that drives renal disease. There ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Gene transfer to treat urinary urgency frequency nocturia and incontinence

    SBC: Ion Channel Innovations, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): This grant application is initiated by Ion Channel Innovations, LLC., (ICI) an early stage biotechnology company that has completed the first, and only, phase I safety trial using plasmid DNA transfer with a non-specific gene MaxiK potassium channel promoter to treat urinary urgency, frequency, nocturia, and incontinence also known as overactive bladder or OAB ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. New In Vitro Human Liver Toxicity Bioassay System

    SBC: Vivo Biosciences Inc            Topic: NIEHS

    DESCRIPTION (provided by applicant): The overall objective of this SBIR proposal is to develop and commercialize a human 3D or mini- liver bioassay system suitable for real-time analysis of metabolic functions and long-term drug toxicity profiles. At present, liver functions are mostly studied using HepG2 cell line and primary hepatocytes cultured onto collagen or polymer matrices. However, these ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Compact, cost-effective, and operator-friendly fundus camera for early detection

    SBC: LUMETRICS, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): This SBIR application will revolutionize the methodology for routine examination of the back of the eye by developing an easy-to-use, pocket-sized, inexpensive digital camera for documenting retinal and optic nerve diseases. In order to reduce rates of preventable vision loss, the early diagnosis of treatable eye diseases has become increasingly important, espe ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. A novel physiologically realistic microfluidic in-vitro blood-brain barrier model

    SBC: CFD RESEARCH CORPORATION            Topic: NIGMS

    DESCRIPTION (provided by applicant): The overall objective of this study is to develop a novel in vitro microfluidic platform to test a drug or delivery vehicle's ability to permeate the Blood-Brain Barrier (BBB). In contrast to current in-vitro models, our proposed device, SIM-BBB, comprises of a microfluidic two-compartment chamber. The chamber is designed in such a way as to permit vis ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Photoactivated Antimicrobial Collagen

    SBC: CONVERSION ENERGY ENTERPRISES            Topic: NIGMS

    DESCRIPTION (provided by applicant): The significance of this project is the development of a novel photoactivated collagen dressing with demonstrated bactericidal effects, minimal toxic effects and low susceptibility to mechanisms of microbial resistancein an effort to ultimately expand the armamentarium of antimicrobial agents for the management of wound infections. Approximately 2 million patie ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Feasibility of Supercritical Carbon Dioxide Sterilization for Absorbable Suture M

    SBC: NOVASTERILIS, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Over the past several decades there has been relatively little innovation in the arena of medical device sterilization. Ethylene oxide (ETO) and gamma irradiation ( irradiation) are the only technologies commerciallyavailable for medical devices. In particular, synthetic polymeric medical devices are sterilized almost exclusively by ETO due to undesirable che ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government